GlassScriptPhysician profile
Erin M Welden
NPI 1376813535
$5,686.41
in general payments reported to CMS, 2019-2025
32 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $197 · 2023: $1,283 · 2024: $2,324 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,774.56 |
| Education | $104.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,052.66 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $633.46 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $482.82 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $441.22 | 2024-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $400.93 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $346.91 | 2022-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.68 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $314.13 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $304.21 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $238.66 | 2022-2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $120.00 | 2025 | |
| Mylan Specialty L.P. | $114.10 | 2023-2024 | Yupelri |
| Inspire Medical Systems, INC. | $108.50 | 2023-2025 | Inspire |
| Amgen INC. | $104.57 | 2023 | Tezspire |
| Paratek Pharmaceuticals, INC. | $90.49 | 2021-2023 | Nuzyra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $85.24 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $77.08 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Axsome Therapeutics, INC. | $61.49 | 2024 | Sunosi |
| Harmony Biosciences LLC | $57.92 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $44.10 | 2025 | Lumryz |
| Insmed, INC. | $38.87 | 2025 | Brinsupri, Arikayce |
| Teva Pharmaceuticals USA, INC. | $38.40 | 2021 | |
| Verona Pharma, INC. | $29.71 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $29.43 | 2021 | |
| Ani Pharmaceuticals, INC. | $26.75 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $22.35 | 2025 | Zemaira |
| Merck Sharp & Dohme LLC | $22.34 | 2024 | Keytruda |
| Viatris Specialty LLC | $22.11 | 2025 | Yupelri |
| Philips North America LLC | $17.40 | 2022 | |
| Scpharmaceuticals INC. | $16.73 | 2024 | |
| Lilly USA, LLC | $14.43 | 2025 | Zepbound |
| Inogen, INC. | $5.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Welden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.